Isofol Medical AB Market Cap ($38.42 Million)
Market Cap & Net Worth: Isofol Medical AB (ISOFOL)
Isofol Medical AB market cap. Isofol Medical AB (ST:ISOFOL) has a market capitalization of $38.42 Million (Skr357.01 Million) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #22663 globally and #426 in its home market, demonstrating a 11.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Isofol Medical AB's stock price Skr1.27 by its total outstanding shares 281107224 (281.11 Million). Also see ISOFOL cash flow conversion for how efficiently the company converts equity into cash flow.
Isofol Medical AB Market Cap History (2017–2026)
Isofol Medical AB market cap history from 2017 to 2026. Data shows change from $662.51 Million to $38.42 Million (-27.30% CAGR). Check Isofol Medical AB stock quote for real-time trading data and today's change.
Isofol Medical AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Isofol Medical AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ISOFOL year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
30.63x
Isofol Medical AB's market cap is 30.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $662.51 Million | $227.00K | -$72.03 Million | 2918.55x | N/A |
| 2020 | $847.05 Million | $37.12 Million | -$188.99 Million | 22.82x | N/A |
| 2021 | $279.53 Million | $22.41 Million | -$200.25 Million | 12.47x | N/A |
| 2022 | $22.39 Million | $12.80 Million | -$159.79 Million | 1.75x | N/A |
| 2023 | $22.08 Million | $721.00K | -$37.07 Million | 30.63x | N/A |
Competitor Companies of ISOFOL by Market Capitalization
Companies near Isofol Medical AB in the global market cap rankings as of November 3, 2026. Also see Isofol Medical AB balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Isofol Medical AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Isofol Medical AB (2017–2026)
Market capitalization of Isofol Medical AB from 2017 to today. Between 2017 and today, Isofol Medical AB's market cap moved from $662.51 Million to $ 38.42 Million, with a yearly change of -27.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr38.42 Million | +74.21% |
| 2025 | Skr22.05 Million | -67.16% |
| 2024 | Skr67.16 Million | +204.11% |
| 2023 | Skr22.08 Million | -1.35% |
| 2022 | Skr22.39 Million | -91.99% |
| 2021 | Skr279.53 Million | -67.00% |
| 2020 | Skr847.05 Million | +38.61% |
| 2019 | Skr611.08 Million | -15.48% |
| 2018 | Skr723.01 Million | +9.13% |
| 2017 | Skr662.51 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Isofol Medical AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.42 Million USD |
| MoneyControl | $38.42 Million USD |
| MarketWatch | $38.42 Million USD |
| marketcap.company | $38.42 Million USD |
| Reuters | $38.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.